The hypotensive efficacies of two vasodilators, hydralazine and minoxidil, were assessed as these drugs were used individually in combination with beta-adrenergic blockade and diuretics in 11 hypertensive patients in whom elevated blood pressure had not been adequately controlled previously by other antihypertensive therapy.
SUMMARY
The hypotensive efficacies of two vasodilators, hydralazine and minoxidil, were assessed as these drugs were used individually in combination with beta-adrenergic blockade and diuretics in 11 hypertensive patients in whom elevated blood pressure had not been adequately controlled previously by other antihypertensive therapy.
Control supine blood pressure fell from 191/128 mm Hg on propranolol and hydrochlorothiazide to 169/108 mm Hg on hydralazine, with a significantly greater reduction to 142/92 mm Hg on minoxidil. Although sodium retention and tachycardia were controlled by the use of concomitant diuretics and beta-blockade, an increment in each of these drugs was occasionally required to prevent these complications. Renal function was changed little with the decrease in blood pressure. Plasma renin increased from a standing control of 14.5 mgg/ml/hr to 35.9 and 31.1 m,gg/ml/hr, respectively, on hydralazine and minoxidil. These data suggest the role of vasodilators used in combination with beta-blockers and diuretics and indicate the greater therapeutic efficacy of minoxidil.
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Propranolol
Renin Aldosterone T HE USE OF drugs which lower blood pressure by direct dilation of the arterial bed appears to be a logical approach to the treatment of systemic hypertension. Such vasodilator drugs will reverse the elevated peripheral vascular resistance characteristics of hypertension without producing the side effects so frequently encountered with drugs that interfere with total adrenergic function.' In a previous study minoxidil, a new vasodilator, was shown to lower blood pressure effectively in hypertensive patients and to have a significantly greater effect when combined with beta-adrenergic blockade with propranolol.2 Beta-blockade itself has recently received considerable attention in the treatment of hypertension.3 4 However, the magnitude of the antihypertensive response with beta-blockade alone has been variable, with some investigators reporting effective control of hypertension using propranolol,5 while others have found minimal reductions using either propranolol6 or newer beta-blocking drugs, alprenolol7 and practolol. 8 In addition, propranolol has been found not to lower vascular resistance, and the observed hypotensive response appears to be the consequence of a reduction in cardiac output.6
It would seem preferable to control blood pressure in hypertension by lowering vascular resistance with direct-acting vasodilators and to use beta-adrenergic blockade secondarily to prevent reflex stimulation of the heart, thus maintaining an unchanged cardiac output. In fact, this approach has been demonstrated using minoxidil combined with propranolol.Ì n the present report we have extended our previous observations with minoxidil2 to compare its therapeutic power or efficacy directly with that of hydralazine, the standard vasodilator available for treatment of hypertension. In this study we have examined the relative antihypertensive efficacy of minoxidil and hydralazine in a group of hypertensive patients who were difficult to manage with conventional antihypertensive therapy. These two vasodilators were used sequentially in the same patients together with beta-blockade and diuretic therapy to inhibit both the reflexly induced tachycardia and the sodium retention that are known to accompany the effect of vasodilators in hypertension.9 Thus, we were able to compare the efficacy of minoxidil with that of hydralazine in the control of severe hypertension.
Methods
Eleven patients were studied ranging from 29 to 55 years of age; seven were males and four were females; two were Negroes. Essential hypertension was present in 10 patients and unilateral renal artery disease complicated by azotemia was present in one (K L A). Severe hypertension was present in spite of the administration of a variety of major antihypertensive drugs together with diuretics in all but one patient (table 1). The sole patient (D A V) not on therapy was unable to tolerate alpha-methyldopa or hydrochlorothiazide because of previous drug reactions and would not accept guanethidine. Side effects of those antihypertensive drugs being used when the patients were considered for the study occurred in seven of the patients. The extent of therapy before inclusion into the study reflected the patients' tolerance to the drugs. In several instances major drugs had been discontinued earlier because of intolerable side effects or lack of response to these drugs.
Retinopathy was present in all, varying from grade II to grade IV. Cardiac evaluation revealed either electrocardiographic evidence of left ventricular hypertrophy or radiographic evidence of left ventricular dilation or both. Three patients had mild to moderate symptoms of hypertensive encephalopathy and one had had a previous subarachnoid hemorrhage. In all but one patient (H U R) renal function was depressed and serum creatinine levels ranged from 1.4 to 7.5 mg/ 100 ml.
A complete description of the experimental nature of the study and of the drugs to be used was presented to all the patients and written consent was obtained. Antihypertensive therapy, with the exception of hydrochlorothiazide, was then discontinued for 1 to 3 weeks in seven patients; in four other patients (B R I, P U L, K A U, and M A C) the patients' clinical status would not justify stopping these drugs during this prestudy period and the patients were admitted to the study without such a preliminary drug-free period.
The patients were hospitalized in the Clinical Research Center of the University of Colorado Medical Center for study. Throughout the study all were placed on a sodium intake that was constant in each patient but varied among the patients from 50 to 160 mEq/day, the level of sodium intake being determined by individual dietary histories. Daily weights were obtained and blood pressures and heart rates were measured four times daily with the patients in the supine and erect positions. Twenty-four hour urine collections were obtained for analysis of creatinine and sodium output together with 3-day stool collections for sodium output which provided the data for sodium balance studies.
Serial laboratory determinations were monitored during a control, hydralazine, and minoxidil period, including chest film, electrocardiogram, lupus erythematosis (LE) preparation, and serum creatinine, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), serum glutamic oxaloacetic transaminase (SGOT), and antinuclear factor. In addition, renal function was measured by clearance techniques using continuous infusion of paraaminohippurate (PAHl) and inulin contained in 0.9% NaCl at a rate of 1 ml/min.10 The urines were collected with spontaneous voiding during a water diuresis. Plasma renin activity and aldosterone concentration were determined during the three study periods by radioimmunoassay;t1 12 bloods were drawn after 8 hours with the patients in the supine fasting state and after 2 hours in the erect position. The data were analyzed by standard statistical methods using Student's ttest for paired data and linear regression analysis.
In eight patients the study was begun with a control period of 4 to 6 days during which these patients received diuretics and propranolol, with the latter administered every 6 hours. In the remaining three patients, a drug-free control period was not present before vasodilator drugs 
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were started and the control values represented those obtained during an initial hospital treatment period on the general medical service prior to transfer to the Clinical Research Ward. These patients (B R I, K A U, and M A C) were all on alpha-methyldopa and hydrochlorothiazide and, in addition, one (K A U) was on guanethidine as well. In these patients the therapy period was begun by adding propranolol and hydralazine simultaneously, continuing hydrochlorothiazide, and discontinuing alpha-methyldopa and guanethidine. Minoxidil and hydralazine were generally given every 6 hours, although those patients who were treated with less than 20 mg of minoxidil daily received the drug less frequently. In one patient (S C H) minoxidil was given prior to hydralazine; following its discontinuance blood pressure remained at the reduced level for at least 9 days, at which time the study was discontinued and the patient discharged. Therefore, in the subsequent 10 patients hydralazine was administered first for 5 to 10 days followed by minoxidil for 7 to 14 days, completing the study. One patient (B R I) was readmitted later while on chronic minoxidil treatment specifically for study of the time of onset and duration of the hypotensive activity of minoxidil.
Results
The therapeutic response to minoxidil was greater than that to hydralazine in these hypertensive patients (table 2) . Hydralazine consistently lowered the blood pressure when the patient was in the recumbent position from an average control level of 191/128 to 169/108 (P <0.01). This hypotensive response was achieved without any orthostatic symptoms and no postural decline in diastolic blood pressure was observed. A moderate decline in systolic blood pressure was observed in nine patients, but this was present in both the control and hydralazine periods. Substitution of minoxidil resulted in a markedly improved antihypertensive effect, with the average blood pressure declining from 169/108 on hydralazine to 142/92 in the group of 10 patients in whom it was possible to compare the minoxidil response directly to that of hydralazine (P < 0.02). Again, there was an orthostatic decline in systolic blood pressure, but here it was of smaller magnitude than in the other periods of observation.
The hospital course of one patient (BAL) particularly emphasizes the therapeutic efficacy of vasodilators when used in combination with beta-adrenergic blockade ( fig. 1) . This patient was difficult to control in clinic because she could not tolerate alpha-methyldopa because of its central nervous system side effects, and guanethidine produced severe postural hypotension in the absence of significant reduction of supine blood pressure. She developed symptoms of hypertensive encephalopathy on hydrochlorothiazide therapy in the clinic and was admitted to the Clinical Research Center because of these symptoms. Initial therapy with alpha-methyldopa was unsatisfactory because of recurrence of somnolence and symptomatic postural hypotension. Consequently, alpha-methyldopa was stopped and propranolol was begun, followed sequentially by hydralazine and then minoxidil. Although some control of blood pressure was effected by hydralazine (600 mg/day), it was only when minoxidil was substituted that adequate blood pressure control was achieved. With supine blood pressures in the 140/88 mm Hg range, systolic postural hypotension was observed, but this was not symptomatic, nor was there any decline in diastolic pressure on standing. The and minoxidil, but the average increase in the group as a whole was insignificant during each treatment period. Although sodium retention was not observed on either vasodilator with the dietary sodium loads that were used, diminished sodium excretion was observed transiently in six of seven patients during minoxidil with the acutely increased sodium load (150 ,Eq/min) used during the renal clearance studies.
Plasma renin was evaluated with the patients in both the supine and erect positions at the end of each study period in seven of 11 patients ( fig. 3) . During the control period plasma renin was elevated in all but two of these patients, with a mean value of 9.3 in the supine position and 14.5 mgg/ml/hr in the erect position. These compared with control values of 1.6 and 3.4 m,ug/ml/hr obtained in normotensive subjects in the supine and erect positions, respectively.'1 Renin values tended to be higher during vasodilator periods with subjects in both the supine and erect positions. However, the increases between the treatment periods when blood pressure was reduced by the vasodilator were significant only when one compared the hydralazine, both supine and erect, or the supine minoxidil values to control values (P < 0.05). It was notable that in spite of a greater reduction in blood pressure during minoxidil, the plasma renin values were somewhat lower than during hydralazine, although these differences were not significant. Indeed, when a comparison of the individual changes in blood pressure were made with the renin values, no overall correlation could be observed between increases in renin and decreases in blood pressure with subjects in either the supine or the erect position. Plasma aldosterone was not consistently altered by either of these two vasodilators in spite of the increased renin levels ( Symptomatic improvement was noted in those three patients who had significant symptomatology in the control period (BAL, BRI, and PUL). These patients all had evidence of mild to moderate encephalopathy, and these findings cleared completely when blood pressures were established within the therapeutic range. Although some improvement of symptoms was observed with the hypotensive effect of hydralazine, it was only with the administration of minoxidil that complete resolution of the patients' symptoms was achieved. Untoward symptoms were minimal in both the hydralazine and minoxidil periods, and these were confined to transient angina in three patients (KLA, KAU, and MAC) during the initiation of minoxidil therapy. This symptom was controlled by adjustment of the minoxidil dosage so that more gradual reduction in blood pressure was accomplished or by increasing the propranolol dosage. The angina occurred without changes in serial electrocardiograms or in serum enzymes.
Clinical studies of potential chemical toxicity of hydralazine, as used in these high doses, and of minoxidil were carried out. No alteration in serum enzymes, antinuclear factor, or LE preparations was observed. Also, the ECG and chest films were unchanged during the two treatment periods.
Discussion
There is a rational physiologic basis in an approach to the therapy of hypertension based The diuretics are drugs of equal importance for use in combination with minoxidil or, in fact, with any vasodilator. Sodium retention has been observed clinically with a variety of vasodilators, and it has been suggested that the renal tubular basis of this response is mediated by enhanced sodium reabsorption in the proximal convoluted tubule. 17 We have shown that small amounts of hydrochlorothiazide are adequate to prevent sodium retention under most circumstances. In three patients with varying degrees of renal insufficiency it was necessary to increase the diuretic therapy to include furosemide during maximal blood pressure reduction with minoxidil. Sodium excretion during the renal clearance studies under the stimulus of a sodium load of 150 gEq/min was in fact reduced in all patients. However, with the exception of the three patients mentioned above, sodium balance was maintained on the individual dietary sodium intakes, suggesting preservation of the capacity to handle sodium under normal circumstances but a defective potential for disposing of large acute sodium loads. The use of diuretics in this study may have been responsible for the fact that approximately equivalent hypotensive responses were achieved with smaller amounts of minoxidil than were employed in our earlier study.2 Furthermore, we observed some moderate postural systolic hypotension in the present study, whereas this was not appreciated earlier with minoxidil. This may have been the result of diuretic therapy which induced a hypovolemia, relative to the dilated vascular bed. It should be emphasized that such hypovolemia may be especially undesirable in the presence of inadequate renal function and in these circumstances might be unnecessary with the use of minoxidil, which has such marked pharmacologic power. Perhaps these patients would have had a similar therapeutic response with smaller amounts of diuretics and larger amounts of minoxidil.
There were no other side effects except those of increased cardiac activity and sodium retention during the short-term evaluation of minoxidil. Headache and palpitations specifically were not encountered. The laboratory tests that were monitored revealed no alteration of-renal or hepatic function. However, moderate hypertrichosis has been observed in five of eight patients on chronic treatment for more than 2 months. The mechanism of this side effect has not been identified. This complication has also been seen with diazoxide.18
Observations on plasma renin were generally consistent with that response which could be anticipated with the use of vasodilators.19 Plasma renin tended to be higher during blood pressure reduction with both vasodilators, although, despite the greater therapeutic response to minoxidil, plasma renin was no greater during that period than during hydralazine. Individual patient responses were not exactly compatible with existing concepts of renin secretion. 20 Thus, changes in plasma renin could not be correlated with individual hypotensive responses or with decreases of sodium output. One important pharmacologic factor in the renin response of this group of patients may be that of propranolol. This drug has been suggested to interfere with renin release,21 and this factor may have played a role in the present observations.
The lack of increase of aldosterone levels as the renin values increased was an unexpected finding in view of the well-established relationship between plasma renin activity and both aldosterone secretion and excretion rates.22 These findings are consistent with our previous measurements of aldosterone excretion, which demonstrated that aldosterone excretion was unchanged in patients treated with minoxidil when they received propranolol concurrently.2 However, the explanation of the failure of aldosterone secretion to increase (as indicated by the -plasma aldosterone concentration) in the face of significant increases in plasma renin is not readily apparent. It is interesting to speculate that propranolol may not only interfere with renin release21 but may alter the effect of the renin stimulus on the secretion of aldosterone either by inhibition of angiotensin I conversion or by a direct effect on the adrenal cortical response to angiotensin II.
As a final point, we have considered how minoxidil, which clearly is effective in severe Circulation, Volume XLV, March 1972 hypertension, may be used clinically. We have made preliminary observations regarding duration and onset of action of the drug when used orally. The hypotensive effect was found to persist for several days after the drug was discontinued ( fig. 4) . After reinstitution of therapy with a single oral dose of the drug, the onset of hypotensive action was rapid, occurring within a few hours. Although the rate at which controlled blood pressure values will return to a hypertensive level when therapy is stopped may be extremely variable, more severely hypertensive patients generally tend to revert more rapidly to their pretreatment levels.23 However, no data directly comparing the duration of action of minoxidil with that of other vasodilators are available at this time. If the suggestion of the prolonged action which we have derived from our clinical observations can be substantiated, minoxidil would provide an important advantage in therapy of hypertension, since patients might be treated with a single daily dose. 
